Curative Biotechnology, Inc.

Equities

CUBT

US23128N1081

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
0.0182 ^USD	-4.21%		-5.21%	-14.55%

May. 06	Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI

Connectyx Technologies Holdings Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 19, 2020 at 10:39 am EDT

Connectyx Technologies Holdings Group, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced net income was USD 363,644 compared to net loss of USD 13,877 a year ago. Basic earnings per share was USD 0.0011. Basic earnings per share from continuing operations was USD 0.0011.

Latest news about Curative Biotechnology, Inc.

Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 06	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	Nov. 25	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	23-09-07	CI
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	23-06-07	CI
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	23-01-05	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	22-11-07	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	22-10-31	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-01	CI
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-29	CI
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors	22-06-16	CI
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors	22-05-12	CI
Curative Biotechnology, Inc. has filed an IPO.	22-04-15	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	22-03-21	CI
Curative Biotechnology, Inc. announced that it has received $1 million in funding	22-03-20	CI
Curative Biotechnology, Inc. announced that it expects to receive $1 million in funding	22-03-03	CI
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration	21-11-24	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	21-11-23	CI
Curative Biotechnology, Inc. Appoints Dr. Catherine Sohn as Special Advisor to Board and CEO	21-10-12	CI
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine	21-10-07	CI
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board	21-09-02	CI
Curative Biotechnology, Inc. has Changed its Ticker to CUBT from CTYX	21-04-29	CI
Curative Biotechnology, Inc. Announces Additions to Scientific and Clinical Advisory Board	21-04-29	CI
Connectyx Technologies Holdings Group, Inc. Announces Management Changes	21-02-11	CI

Chart Curative Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURATIVE BIOTECHNOLOGY, INC.	-14.55%	17.16M
MODERNA, INC.	+55.55%	59.34B
LONZA GROUP AG	+43.17%	40.24B
IQVIA HOLDINGS INC.	-4.71%	39.88B
CELLTRION, INC.	-5.56%	28.55B
ICON PUBLIC LIMITED COMPANY	+13.76%	27.26B
ALNYLAM PHARMACEUTICALS, INC.	-22.00%	19.23B
MEDPACE HOLDINGS, INC.	+31.50%	12.61B
BIO-TECHNE CORPORATION	+2.16%	12.49B
UNITED THERAPEUTICS CORPORATION	+25.70%	12.28B

Other Biotechnology & Medical Research